Brown K W, Watson J E, Poirier V, Mott M G, Berry P J, Maitland N J
Department of Pathology and Microbiology, School of Medical Sciences, University Walk, Bristol, UK.
Oncogene. 1992 Apr;7(4):763-8.
A candidate gene (WT1) has recently been described for the 11p13 tumour-suppressor gene involved in the development of Wilms' tumour. This gene encodes a zinc finger protein which can bind to a specific DNA sequence. We have found a 226 base deletion in the mRNA from a unilateral Wilms' tumour, which would cause a frameshift that completely deletes the zinc finger domain. The tumour developed in a patient suffering from the WAGR syndrome, who had a constitutional 11p13 deletion, and so the 226 base deletion represents the inactivation of the remaining WT1 allele in the tumour. This provides further direct evidence that loss of function of WT1 is an essential step in the development of Wilms' tumour.
最近发现了一个与11p13肿瘤抑制基因相关的候选基因(WT1),该基因参与肾母细胞瘤的发生发展。此基因编码一种能与特定DNA序列结合的锌指蛋白。我们在一例单侧肾母细胞瘤的mRNA中发现了一个226个碱基的缺失,这将导致移码突变,从而完全删除锌指结构域。该肿瘤发生于一名患有WAGR综合征的患者,其存在11p13染色体的先天性缺失,因此这226个碱基的缺失代表肿瘤中剩余WT1等位基因的失活。这进一步提供了直接证据,表明WT1功能丧失是肾母细胞瘤发生发展的关键步骤。